Brief: Atreca Presents Data From Ongoing Phase 1B Study Of ATRC-101 In Patients With Select Advanced Solid Tumors During Oral Abstract Session At The ASCO 2023 Annual Meeting
05/06/2023 16:08
June 5 (Reuters) - Atreca Inc BCEL.O :
* ATRECA PRESENTS DATA FROM ONGOING PHASE 1B STUDY OF
ATRC-101 IN
PATIENTS WITH SELECT ADVANCED SOLID TUMORS DURING ORAL ABSTRACT
SESSION AT THE ASCO 2023 ANNUAL MEETING
* ATRECA INC - ATRC-101 CONTINUES TO BE WELL-TOLERATED
Source text for Eikon: ID:nGNX94gtKz
Further company coverage: BCEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atreca
See all newsBrief: Baker Bros Advisors Reports 19.99% Passive Stake In Atreca As Of Dec 31, 2023 - SEC Filing
Brief: Immunome To Acquire Antibody-Related Assets And Materials From Atreca
Brief: Atreca Says On Dec 19 Asset Sale And Other Transactions Contemplated By Agreement, Board Approved Liquidation And Dissolution Of Co
Brief: Atreca Q3 basic EPS USD -0.92
Brief: Atreca Announces Agreement To Terminate Lease And Departure Of CFO Herb Cross